# US 5,705,180 A · Therapeutic agent for the treatment of melanomas > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,705,180 A - Document ID: US5705180A - Status: Granted - Kind: A - Application number: 08/525,665 - Filed: 1995-09-22 - Granted: 1998-01-06 - Earliest claimed: 1993-03-22 - Assignees: Betatene Limited - Inventors: Lance Elliott Schlipalius - Web page: https://patentgrep.com/patent/US5705180A ## CPC - A61K 31/015: carbocyclic - A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)} - A61K 9/1274: Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases - A61P 17/00: Drugs for dermatological disorders - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides a therapeutic agent for the treatment of a melanoma or melanomas by injection or intravenously including a mixture of: (a) a water soluble dispersible component; (b) an emulsifier component; and (c) a water insoluble carotenoid component in a suitable carrier medium. ## Claims ### Claim 1 A method of treatment of a melanoma or melanomas including the step of introducing directly into the bloodstream or melanoma an effective amount of a therapeutic agent comprising a mixture of: (a) a sugar alcohol; (b) a glyceride; and (c) a therapeutically effective amount of a water insoluble carotenoid for treatment of melanoma or melanomas, in oil. ### Claim 2 (depends on 1) The method of treatment of a melanoma or melanomas according to claim 1, wherein the effective amount is from 0.1 to 10.0 micrograms/ml of the therapeutic agent contacting the melanoma cells. ### Claim 3 (depends on 1) The method of treatment of a melanoma or melanomas according to claim 1, wherein the effective amount is from 0.1 to 3.0 micrograms/ml of the therapeutic agent contacting the melanoma cells. ### Claim 4 (depends on 1) A method of treatment of a melanoma or melanomas according to claim 1, wherein the introduction of the therapeutic agent into the bloodstream is by injection or intravenously. ### Claim 5 (depends on 1) A method of treatment of a melanoma or melanomas according to claim 1, wherein the introduction of the therapeutic agent directly into the site of the melanoma or melanomas is by injection. ### Claim 6 A therapeutic agent for the treatment of a melanoma or melanomas comprising a mixture of: (a) a sugar alcohol; (b) a glyceride; and (c) a therapeutically effective amount of a water insoluble carotenoid for treatment of a melanoma or melanomas, in oil. ### Claim 7 (depends on 6) A therapeutic agent according to claim 6 wherein the sugar alcohol is in the range of 30% to 90% by weight. ### Claim 8 (depends on 6) A therapeutic agent according to claim 6, wherein the sugar alcohol is glycerol. ### Claim 9 (depends on 8) A therapeutic agent according to claim 8, wherein the glycerol is in the range of 30% to 90% by weight. ### Claim 10 (depends on 6) A therapeutic agent according to claim 6, wherein the glyceride is in the range of 0.2% to 20% by weight. ### Claim 11 (depends on 6) A therapeutic agent according to claim 6, wherein the glyceride is in the range of 1.0% to 10% by weight. ### Claim 12 (depends on 6) A therapeutic agent according to claim 6, wherein the glyceride is glyceryl mono-oleate. ### Claim 13 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid component comprises beta-carotene. ### Claim 14 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid composition comprises 2% to 50% by weight beta-carotene in soya bean oil. ### Claim 15 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid composition comprises 20% to 40% by weight beta-carotene in soya bean oil. ### Claim 16 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid composition comprises 30% by weight beta-carotene in soya bean oil. ### Claim 17 (depends on 16) A therapeutic agent according to claim 16, wherein the beta-carotene comprises cis beta-carotene and all trans beta-carotene. ### Claim 18 (depends on 17) A therapeutic agent according to claim 17, wherein the beta carotene comprises 50% to 90% cis beta-carotene. ### Claim 19 (depends on 17) A therapeutic agent according to claim 17, wherein the beta-carotene comprises 70% to 85% cis beta carotene. ### Claim 20 (depends on 17) A therapeutic agent according to claim 17, wherein the cis beta-carotene comprises 9 cis beta-carotene. ### Claim 21 (depends on 17) A therapeutic agent according to claim 17, wherein the cis beta-carotene comprises 50% to 90% 9 cis beta-carotene. ### Claim 22 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid component of the composition is in the range of 0.1% to 10% by weight. ### Claim 23 (depends on 6) A therapeutic agent according to claim 6, wherein the water insoluble carotenoid composition is in the range of 1% to 5% by weight. ### Claim 24 (depends on 6) A therapeutic agent according to claim 6, wherein the vegetable oil is in the range of 1% to 40% by weight. ### Claim 25 (depends on 6) A therapeutic agent according to claim 6, wherein the carrier medium is in the range of 1% to 20% by weight. ### Claim 26 (depends on 6) A therapeutic agent according to claim 6, wherein the agent is diluted for direct introduction into the bloodstream or melanoma or melanomas of an effective amount of the composition. ### Claim 27 (depends on 26) A therapeutic agent according to claim 26, wherein the agent is diluted by aqueous buffers, normal intravenous preparations, blood serum, or combinations thereof.